Engage:BDR Share Purchase Plan closes today

Published 06-JUN-2018 15:28 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

With the tech small cap having extended the close date for its Share Purchase Plan (SPP) beyond 29 May, eligible shareholders in engage:BDR (ASX:EN1) still have the opportunity to participate in the current SPP until close of business today.

The placement opportunity allows shareholders to subscribe for up to an additional A$15,000 of new ordinary shares in the company at an issue price of A$0.16, subject to scale back in the company's absolute discretion. The SPP is not underwritten.

Via the SPP offer, EN1 aims to raise approximately A$2 million to go towards conducting due diligence on the proposed acquisition of AdCel Inc (announced in May), the cash component of the proposed acquisition price, and other working capital requirements for the company.

The company’s proprietary platform utilises sophisticated technology to buy and sell advertising, making the process a lot faster, more cost efficient and also highly scalable.

EN1 launched its own video-serving platform in 2015, eliminating third-party dependency and dramatically reducing its operating costs. It then entered an era of increased investment in technology, to subsequently become a major player in digital advertising across both programmatic advertising as well as the trend of digital influencer marketing.

The most recent headline-grabbing news from the company was its major deal with new cryptocurrency ivyKoin. ivyKoin is a blockchain-based cryptocurrency designed to facilitate transparent business payments on a global scale (you can read an in-depth article on ivyKoin here). In essence, ivyKoin is designed for business transactions, in particular larger financial transactions requiring extensive verification.

Prior to this news, in January EN1 also launched its influencer marketing platform ‘IconicReach’ at the Sundance Film Festival — the largest independent film festival in the US. The platform, developed by the Los Angeles-based tech play over the last two years, utilises EN1’s proprietary technology to streamline the previously inefficient process of sourcing, transacting, and executing influencer campaigns.

Yet EN1 does remain a speculative investment and investors should take a cautious approach to any investment decision made with regard to this stock.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X